Duvelisib - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for duvelisib and what is the scope of freedom to operate?

Duvelisib is the generic ingredient in one branded drug marketed by Secura and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Duvelisib has one hundred and thirty-seven patent family members in thirty-one countries.

Summary for duvelisib

International Patents:	137
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Bulk Api Vendors:	61
Clinical Trials:	31
Patent Applications:	827
Drug Prices:	Drug price trends for duvelisib
What excipients (inactive ingredients) are in duvelisib?	duvelisib excipients list
DailyMed Link:	duvelisib at DailyMed

See drug prices for duvelisib

Recent Clinical Trials for duvelisib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
John Kirkwood	Phase 1/Phase 2
Emory University	Phase 2
University of Pennsylvania	Phase 2

See all duvelisib clinical trials

US Patents and Regulatory Information for duvelisib

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-002	Sep 24, 2018		RX	Yes	Yes	Start Trial	Start Trial				Start Trial
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	Start Trial	Start Trial				Start Trial
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	Start Trial	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for duvelisib

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	2011509259	Start Trial
South Korea	101875720	Start Trial
South Korea	20100126287	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.